BioLineRx Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of January 2025, with the filing date of January 6, 2025. BioLineRx Ltd., a foreign private issuer based in Modi'in, Israel, filed this report to disclose a recent equity offering and incorporate a press release issued on the same date.
Key Financial Metrics
The filing details a specific capital raising activity rather than comprehensive financial statements for a fiscal period.
- Equity Offering: Sold 5,676,396 American Depositary Shares (ADS).
- Share Structure: Each ADS represents 15 ordinary shares with a par value of NIS 0.10.
- Gross Proceeds: Approximately $1.6 million.
- Sales Mechanism: "At-the-market" equity offering program with H.C. Wainwright & Co., LLC as the sales agent.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes
The primary material change reported is the increase in outstanding share count and the infusion of capital through the sale of ADSs during January 2025. No comparative financial data against prior periods is included in this specific filing.
Guidance, Outlook, and Risks
This filing does not contain management commentary, forward-looking guidance, or specific risk factors. It serves primarily as a notification of the share sale and incorporates a press release (Exhibit 1) by reference, the content of which is not detailed in the provided text.
Investor Verification Checklist
- Verify the exact weighted average price per ADS derived from the $1.6 million gross proceeds and 5,676,396 shares sold.
- Review the attached Exhibit 1 press release for details on the intended use of the $1.6 million in proceeds.
- Confirm the total number of outstanding ADSs post-transaction to assess dilution impact.
- Check the status of the "at-the-market" offering program to determine if further sales are planned.